These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 33902046

  • 1. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
    Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Trejo Rosales R, Rojas L, Cruz-Rico G, Nagy R, Cabrera L, Vargas C, Saam J, Barrón F, Arrieta O.
    Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
    [Abstract] [Full Text] [Related]

  • 2. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR.
    Cancer; 2020 Jul 15; 126(14):3219-3228. PubMed ID: 32365229
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.
    Ann Oncol; 2019 Feb 01; 30(2):290-296. PubMed ID: 30535340
    [Abstract] [Full Text] [Related]

  • 6. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
    Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR.
    Ann Oncol; 2019 Apr 01; 30(4):597-603. PubMed ID: 30891595
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May 01; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
    McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC.
    Clin Cancer Res; 2018 Jun 15; 24(12):2758-2770. PubMed ID: 29599410
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
    Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K.
    Cancer Med; 2023 Dec 15; 12(23):21097-21110. PubMed ID: 37948122
    [Abstract] [Full Text] [Related]

  • 13. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
    Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ.
    Mod Pathol; 2018 Feb 15; 31(2):307-312. PubMed ID: 28914263
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ.
    JCO Precis Oncol; 2024 Jan 15; 8():e2300314. PubMed ID: 38190582
    [Abstract] [Full Text] [Related]

  • 15. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M, Mukhopadhyay M, Das C, Chatterjee S, Naskar BG.
    J Cancer Res Ther; 2021 Jan 15; 17(6):1389-1396. PubMed ID: 34916369
    [Abstract] [Full Text] [Related]

  • 16. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, Sakao Y, Yatabe Y.
    Cancer; 2017 May 15; 123(10):1731-1740. PubMed ID: 28177518
    [Abstract] [Full Text] [Related]

  • 17. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.
    Clin Lung Cancer; 2018 Sep 15; 19(5):e601-e608. PubMed ID: 29807856
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.